Hørsholm, Denmark

Lykke Pedersen

This inventor holds 25 USPTO granted patents and 37 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Oligonucleotide Development. Top assignees: Hoffmann-La Roche Inc., Roche Innovation Center Copenhagen A/s, Other. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lykke Pedersen. Retrieved from https://idiyas.com/inventor/lykke-pedersen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 6.2

ph-index = 4

Forward Citations = 37(Granted Patents)


Location History:

  • Horsholm, DK (2020 - 2023)
  • Copenhagen, DK (2022 - 2023)
  • Hørsholm, DK (2019 - 2024)

Company Filing History:


Years Active: 2019-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Oligonucleotides
UBE3A Expression
PD-L1 Reduction
FUBP1 Modulation
Antisense
Nucleic Acid Molecules
RTEL1 Expression
HTRA1 Expression
PAPD5
PAPD7
SCN9A
25 patents (USPTO):Explore Patents

Title: Lykke Pedersen: Innovator in Oligonucleotide Technologies

Introduction

Lykke Pedersen, a proficient inventor based in Hørsholm, Denmark, has made significant strides in the field of oligonucleotide technologies. With an impressive portfolio of 18 patents, she has developed innovative approaches for modulating gene expressions, particularly in the context of pain management and viral infections.

Latest Patents

Among her latest inventions, Lykke Pedersen has patented two notable innovations. The first is focused on "Oligonucleotides for Modulating SCN9A Expression," wherein she describes oligonucleotides that are complementary to nucleic acids encoding the voltage-gated sodium channel Na1.7. These oligonucleotides have the potential to inhibit the expression of Na1.7, offering novel therapeutic avenues for pain prevention and treatment. Her second patent, "Enhanced Oligonucleotides for Inhibiting RTEL1 Expression," presents antisense oligonucleotides that target RTEL1 and may be used to treat and prevent hepatitis B virus (HBV) infections, along with related pharmaceutical compositions.

Career Highlights

Lykke Pedersen has amassed a rich career, working with esteemed organizations such as Hoffmann-La Roche Inc. and Roche Innovation Center Copenhagen A/S. These positions have allowed her to leverage her expertise in biotechnology and drug development, further advancing innovations in molecular medicine.

Collaborations

Throughout her career, Lykke has collaborated with distinguished professionals like Søren Vestergaard Rasmussen and Søren Ottosen. These collaborations have fostered a multidimensional approach to her research, enriching her contributions to the field of biotechnology.

Conclusion

Lykke Pedersen stands out as a leading innovator in the biotechnology sector, primarily through her pioneering work with oligonucleotide technologies. Her groundbreaking patents reflect a commitment to addressing critical healthcare challenges, particularly in pain management and infectious diseases. As the field progresses, her contributions are sure to inspire ongoing advancements in molecular therapeutics.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…